Courier Capital LLC Sells 254 Shares of Danaher Co. (NYSE:DHR)

Courier Capital LLC lowered its stake in Danaher Co. (NYSE:DHR) by 13.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,671 shares of the conglomerate’s stock after selling 254 shares during the period. Courier Capital LLC’s holdings in Danaher were worth $387,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. State Street Corp boosted its holdings in Danaher by 3.2% in the second quarter. State Street Corp now owns 27,962,346 shares of the conglomerate’s stock valued at $6,718,427,000 after acquiring an additional 866,600 shares in the last quarter. Wellington Management Group LLP lifted its position in Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares during the period. Moneta Group Investment Advisors LLC lifted its position in Danaher by 96,490.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock valued at $6,180,839,000 after buying an additional 23,262,904 shares during the period. Bank of New York Mellon Corp lifted its position in Danaher by 6.5% during the third quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock valued at $2,030,327,000 after buying an additional 502,868 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Danaher by 1.7% during the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after purchasing an additional 134,905 shares during the period. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on DHR shares. The Goldman Sachs Group lowered Danaher from a “buy” rating to a “neutral” rating and decreased their price target for the company from $215.00 to $205.00 in a report on Thursday, December 7th. JPMorgan Chase & Co. upped their price objective on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Wolfe Research began coverage on Danaher in a research note on Wednesday, December 13th. They issued a “peer perform” rating for the company. KeyCorp raised their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Barclays lowered Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 price target on the stock. in a report on Wednesday, January 24th. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $266.00.

Insider Activity

In other news, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri List sold 3,289 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Up 0.2 %

DHR opened at $248.84 on Thursday. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. The stock’s fifty day moving average is $246.68 and its 200-day moving average is $230.40. The company has a market capitalization of $184.07 billion, a PE ratio of 38.94, a P/E/G ratio of 3.77 and a beta of 0.84.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. Danaher’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.87 earnings per share. On average, equities analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s payout ratio is currently 15.02%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.